Onecell Medical Company
"Multi-parametric Single Cell Analysis Device."
OneCell Medical, co-founded by Technion president, Prof. Uri Sivan, and backed by Sanara Ventures develops a unique multi-parametric single-cell analysis device. The technology is capable of simultaneously capturing thousands of cells and immune-phenotype/characterize each cell as well as provide the RNA sequence of a desired target.
Due to the COVID-19 outbreak, OneCell pivoted its development towards identifying rapidly antibodies' (mRNA) sequences capable of neutralizing the virus. With turnaround time of 36 hours from sample to sequence and unmatched cells capturing yield, the technology can help in the rapid identification of anti-viral neutralizing antibodies for COVID19 therapy as well as any other future or mutated viral agent.
The company’s approach is also highly relevant to personalized medicine in general. Before the COVID19 outbreak the company developed Personalized Cancer Cell Immune Therapy to be applied for solid tumors, an unmet need.
OneCell Medical is supported by the Incubator Program of Israel Innovation Authority as well as Sanara Ventures and Technion.
Combating Coronavirus Pandemic:
Onecell Medical's solution helps address the Coronavirus Pandemic.
OneCell Medical, co-founded by Technion president, Prof. Uri Sivan, and backed by Sanara Ventures develops a unique multi-parametric single-cell analysis device. The technology is capable of simultaneously capturing thousands of cells and immune-phenotype/characterize each cell as well as provide the RNA sequence of a desired target.
Due to the COVID-19 outbreak, OneCell pivoted its development towards identifying rapidly antibodies' (mRNA) sequences capable of neutralizing the virus. With turnaround time of 36 hours from sample to sequence and unmatched cells capturing yield, the technology can help in the rapid identification of anti-viral neutralizing antibodies for COVID19 therapy as well as any other future or mutated viral agent.
The company’s approach is also highly relevant to personalized medicine in general. Before the COVID19 outbreak the company developed Personalized Cancer Cell Immune Therapy to be applied for solid tumors, an unmet need.
OneCell Medical is supported by the Incubator Program of Israel Innovation Authority as well as Sanara Ventures and Technion.
Combating Coronavirus Pandemic:
Onecell Medical's solution helps address the Coronavirus Pandemic.
Technology:
COVID Treatments
Industry:
Treatment Development
Headquarters:
Israel
Founded Date:
2017
Employees Number:
N/A
Funding Status:
N/A
Register and Claim Ownership